drugset / Trial / NCT00210327
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses)of bortezomib in pretreated MALT lymphomas with one prior sistemic therapy regimen
Timeline
- Start
- 2005-07
- Primary completion
- 2008-11
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |